QT-Prolongation in Lung Transplantation (TX-QTC)
Experimental intervention: electrocardiography. Control intervention: none
Duration of intervention per patient/subject:
5 min, observation 6 months
Key inclusion criteria:
- outpatients after lung transplantation (single, double or combined)
- outpatients on the wait list for lung transplantation
Key exclusion criteria:
• no informed consent
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary endpoint:
• prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation
Key secondary endpoint(s):
- prevalence of any QTc-interval prolongation (>440 msec ) after lung transplantation
- prevalence of PQ prolongation (200 msec sec or above) after lung transplantation
- prevalence of QRS prolongation (120 msec or above) after lung transplantation
- prevalence of QTc-prolonging drugs in drug regimen before and after lung transplantation
- influence of long-term neo-macrolide (e.g. azithromycin) on QTc interval after lung transplantation
- intra-individual difference of QTc interval before and after lung transplantation
- incidence of any QTc-interval prolongation(>440 msec ) after lung transplantation
- incidence of any QTc-interval prolongation (>440 msec or increase by 50msec or above) after initiation of new QTc prolonging drugs (especially neo-macrolides)
- reversal of QTc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any QTc prolonging drug
- Assessment of safety:
- Incidence of new onset heart rhythm disorder during 6 months of follow-up
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Susanne Hoyer, MD
- Phone Number: 00495115324601
- Email: hoyer.susanne@mh-hannover.de
Study Contact Backup
- Name: Jens Gottlieb, MD
- Phone Number: 00495115324681
- Email: gottlieb.jens@mh-hannover.de
Study Locations
-
-
-
Hannover, Germany, 30625
- Department of Respiratory Medicine, Medizinische Hochschule Hannover
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- outpatients after lung transplantation (single, double or combined)
- outpatients on the wait list for lung transplantation
Exclusion Criteria:
- no informed consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Outpatients on the Waiting List and after Lung Transplantation
Electrocardiography
|
Duration of intervention per patient/subject: 5 min, observation 6 months |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jens Gottlieb, MD, Hannover MS, Dpt Respiratory Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2602-2015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.